Annual Press Conference 2011 - Boehringer Ingelheim

More documents

Recommendations

Info

Businesses and Financial Figures 2010 Hubertus von Baumbach Corporate Board Division Finance and Animal Health
Challenges of 2010 well managed Continued strong financial stability in EUR million 2009 2010 Change Net sales 12,721 12,586 –1% Operating income 2,239 1,896 –15% BilMoG Effect 0 –594 –100% Net income 1,759 888 –50% Equity ratio 39.3% 39.9% +0.6 Liquidity 5,384 6,113 +13% Annual Press Conference 2011 • Growth of ongoing business +5.5% • R&D expenses: EUR 2,453 million • Change in pension accounting • Solid financing 11
Page 1 and 2: Annual Press Conference 2011 Busine
Page 3 and 4: Highlights of the business year 201
Page 5 and 6: PRADAXA® for Stroke Prevention in
Page 7 and 8: Our Businesses Net sales maintained
Page 9: Key Messages 2010 125 years more he
Page 13 and 14: Prescription Medicines Strong core
Page 15 and 16: Consumer Health Care Continued grow
Page 17 and 18: Top 10 Global Corporations 2010 in
Page 19 and 20: Animal Health Strong growth of 5 co
Page 21 and 22: Industrial Customer Business (ICB)
Page 23 and 24: Dynamic growth in emerging markets
Page 25 and 26: Operating Cash Flow covers investin
Page 27 and 28: The basis of longterm independence
Page 29 and 30: Outlook 2011 Andreas Barner Chairma
Page 31 and 32: Diabetes: Alliance with Eli Lilly a
Page 33 and 34: Biopharmaceuticals: Our Sites Cell
Page 35 and 36: Innovative power of our employees a
Page 37: Annual Press Conference 2011 Busine

Annual Press Conference 2011 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?